CSL Limited

CSL Limited (ASX:CSL) Share Price, Buyback and 2026 Outlook: Latest News and Forecasts as at 5 December 2025

CSL Limited’s share price is still nursing some heavy bruises, but under the surface the story in December 2025 is more “complex reboot” than simple “fallen giant”. On 5 December 2025, the ASX healthcare heavyweight is trading near multi‑year lows

5 December 2025

CSL Limited (ASX:CSL) Share Price on 4 December 2025: Restructuring Fallout, New Vaccine Plant and 2026 Stock Forecast

Updated: 4 December 2025 CSL Limited (ASX:CSL), the Australian biotech heavyweight, is trading around A$183 per share on 4 December 2025 after one of the most bruising years in its modern history. The company has delivered solid profit growth, announced

4 December 2025

ASX Updates · Company Analysis · Healthcare Industry · Investment Forecasts · Share Market News

CSL Limited (ASX:CSL) Stock Outlook on 2 December 2025: Share Price Slump, Seqirus Spin-Off, New Vaccine Plant and a A$750m Buyback

Updated: 2 December 2025 CSL Limited’s share price has spent most of 2025 in the sin bin, but behind the drawdown sits a mix of solid earnings growth, a radical restructuring, a forthcoming spin‑off of its vaccines arm and fresh

2 December 2025

Corporate News · CSL Limited · Healthcare Industry · Investment Analysis · Stock Market

CSL Limited (ASX:CSL) Share Price, Latest News and 2026 Outlook as of 1 December 2025

CSL Limited heads into the 1 December 2025 ASX session as one of Australia’s most closely watched blue‑chip stocks. After a year of guidance cuts, a delayed vaccine spin‑off and a shareholder revolt, the biotech giant trades around the mid‑A$180s

1 December 2025

ASX News · Company Analysis · Financial Outlook · Investment · Stock Market

CSL Limited (ASX:CSL) Shares: Cost Cuts, Buyback and US Expansion – What to Watch Before the ASX Opens on 1 December 2025

CSL Limited (ASX:CSL) goes into Monday’s ASX open on 1 December 2025 as one of the market’s most hotly debated blue chips – bruised by profit downgrades and a delayed spin‑off, yet backed by a large buyback, a US$1.5 billion

30 November 2025

ASX News · Company Analysis · Financial Updates · Investment Strategies · Stock Market

CSL Limited (ASX:CSL) Share Price Today, 28 November 2025 – Is the Worst Finally Priced In?

On Friday, 28 November 2025, CSL Limited (ASX:CSL) edged higher as investors continued to digest a bruising year of profit downgrades, a delayed spin-off, and aggressive cost-cutting – all against the backdrop of a sizeable on-market share buyback and new

28 November 2025

ASX Updates · CSL News · Investment Insights · Share Market · Stock Analysis

CSL Limited (ASX:CSL) Stock Today: Buyback Update, Share Price Action and Outlook – 27 November 2025

Sydney – Thursday, 27 November 2025 CSL Limited (ASX:CSL) enters the final month of 2025 still nursing one of the toughest years in its history. After profit downgrades, a delayed vaccine spin‑off and a brutal share-price slump, the biotech giant

27 November 2025

CSL Limited · Investment Analysis · Market Outlook · Share Buybacks · Stock Market

CSL Limited (ASX:CSL): What You Need to Know Before the Market Opens on 24 November 2025

CSL Limited (ASX:CSL), long considered one of the ASX’s safest growth names, heads into Monday’s open on 24 November 2025 under a very different spotlight. A bruising year of profit downgrades, restructuring, and a sharp share price fall has collided

23 November 2025

Australian Stocks · Company Updates · Investment Tips · Market Analysis · Market Opening

CSL Limited (ASX: CSL) pre‑open brief for 17 November 2025: Buy‑back in full swing, Seqirus spin‑off delayed, guidance cut — here’s what matters

CSL Limited heads into Monday’s open with investors still digesting a tough few months: a surprise guidance downgrade and delayed vaccines demerger at the late‑October AGM, followed by a steady drumbeat of daily buy‑back notices last week. Below is a

16 November 2025

ASX Updates · Company News · Corporate Actions · Investment Insights · Market Analysis